Pacific Biosciences of California (PACB) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Todd Friedman - Senior Director, FP&A and Investor RelationsChristian Henry - President & Chief Executive OfficerTom Nikic - Managing Director, Equity ResearchJim Gibson - CFOHarrison Parsons - Equity Research AssociateWilliam Ruby - Equity Research Associate Conference Call Participants Jake Titleman - AnalystJack Meehan - Equity Research AnalystAlex Vukasin - VP Healthcare Equity Research AnalystDa ...

PacBio Q1 2025 Earnings Presentation May 8, 2025 First Quarter 2025 Earnings Call 1 Statement regarding use of non‐GAAP financial measures This presentation contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to PacBio's cost-saving plans and initiatives as w ...

Revenue Performance - Preliminary Q1 2025 revenue was $36.9 million, a decrease of 5% from $38.8 million in Q1 2024[3]. - Instrument revenue declined to $10.8 million from $19.0 million year-over-year, while consumable revenue increased to a record $20.1 million from $16.0 million[3][4]. - The full-year 2025 revenue guidance remains at $155 million to $170 million[7]. Cost Management - The company plans to reduce annualized non-GAAP operating expenses by $45 million to $50 million, adjusting previous guidance from $270 million to $280 million[5][9]. - The company expects 2025 non-GAAP gross margin to be between 35% and 40%[15]. Sales and Demand - Annualized Revio pull-through per system was approximately $236,000, consistent with expectations in the low to mid $200,000s range[4][15]. - Vega system orders accelerated in Q1 2025 compared to Q4 2024, indicating strong demand from both new and existing customers[4]. Financial Position - Cash, cash equivalents, and investments totaled $343.1 million, down from $561.9 million in Q1 2024[3]. Organizational Changes - The company is restructuring its commercial organization to improve sales force efficiency while maintaining customer service across all segments[6]. Future Outlook - PacBio aims to achieve positive cash flow by the end of 2027 despite ongoing market uncertainties[6].

MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results: Q1 2025Q1 2024Revenue$37.2 million$38.8 millionInstrument revenue$11.0 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 million<td style="borde ...

Core Insights - PacBio and Chulalongkorn University have announced a strategic collaboration to implement PacBio's HiFi whole genome sequencing (WGS) in a newborn screening research program, marking the first initiative of its kind in the Asia Pacific region [1][2] - The collaboration aims to enhance the identification of rare and treatable conditions in newborns through comprehensive genomic data, positioning Thailand as a leader in precision medicine [1][3] Company Overview - PacBio is a leading provider of high-quality sequencing platforms, focusing on advanced sequencing solutions that address complex genetic problems across various research applications, including human germline sequencing and oncology [4] - The company's HiFi long-read sequencing technology is designed to generate highly accurate and complete genomic data, enabling the detection of a wider range of genetic variants [2][4] Industry Context - Traditional newborn screening programs have been limited to targeted panels, but advances in genome sequencing allow for a broader approach that can identify conditions from birth [2] - The collaboration reflects a growing trend in the Asia Pacific region towards integrating whole genome sequencing into national healthcare strategies, particularly in newborn screening [3]

Company Performance - Pacific Biosciences of California (PACB) closed at $1.11, reflecting a -1.77% change from the previous day, underperforming the S&P 500's gain of 0.58% [1] - Over the past month, PACB shares have decreased by 4.24%, compared to a 5.22% loss in the Medical sector and a 0.84% loss in the S&P 500 [1] Upcoming Earnings - The company is expected to report an EPS of -$0.19, which represents a 26.92% increase from the same quarter last year [2] - The Zacks Consensus Estimate for revenue is projected at $35 million, indicating a decline of 9.82% from the previous year [2] Fiscal Year Estimates - For the entire fiscal year, the Zacks Consensus Estimates predict an EPS of -$0.71 and revenue of $158.74 million, reflecting changes of +14.46% and +3.07% respectively from the prior year [3] Analyst Estimates - Recent changes in analyst estimates for Pacific Biosciences are important as they reflect short-term business trends, with positive revisions indicating analyst optimism about the company's profitability [4] - The Zacks Consensus EPS estimate has decreased by 0.95% in the past month, and the company currently holds a Zacks Rank of 3 (Hold) [6] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 54, placing it in the top 22% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Insights - PacBio has licensed advanced deep learning-based DNA methylation detection methods from The Chinese University of Hong Kong (CUHK) to enhance its HiFi sequencing capabilities, specifically for detecting 5-hydroxymethylcytosine (5hmC), hemimethylated 5-methylcytosine (5mC), and N6-methyladenine (6mA) [1][2][4] Technology and Innovation - The licensed technology includes the Holistic Kinetic Model 2 (HK2), which utilizes an AI deep learning framework to improve the accuracy of methylation detection, including the ability to call native 5hmC in single molecules, a first for HiFi sequencing [2][4] - HiFi sequencing on Revio and Vega platforms allows for comprehensive genome and epigenome readouts from native DNA without chemical conversion or additional sample preparation, enhancing the efficiency of sequencing workflows [3][6] Market Impact - The integration of HK2 is expected to set a new standard for accuracy in DNA methylation detection, particularly for 5mC and 5hmC, which are crucial for research in cancer and human development [4][7] - Institutions like Children's Mercy Kansas City and GeneDx are already utilizing HiFi sequencing for genomic and epigenomic profiling, indicating a growing adoption of this technology in clinical settings [5] Future Prospects - The new capabilities from HK2 will be delivered to existing customers through software updates, ensuring no additional costs or changes to current sequencing protocols [3][8] - The ability to profile 5hmC is anticipated to open new avenues in liquid biopsy and cancer detection, maintaining DNA integrity and supporting haplotype-resolved analysis [6][8]

Pacific Biosciences of California (PACB) closed the most recent trading day at $1.17, making no change from the previous trading session. The stock's change was less than the S&P 500's daily gain of 1.67%. Meanwhile, the Dow experienced a rise of 1.07%, and the technology-dominated Nasdaq saw an increase of 2.5%.The the stock of maker of genetic analysis technology has fallen by 10.69% in the past month, lagging the Medical sector's loss of 9.34% and the S&P 500's loss of 6.57%.Market participants will be c ...

Core Viewpoint - The Davos Alzheimer's Collaborative (DAC) is launching the North African Dementia Registry (NADR) project in collaboration with PacBio, The American University in Cairo (AUC), and UCL to enhance understanding of Alzheimer's disease and dementia in diverse populations, particularly in North Africa [1][2][3] Group 1: Project Overview - The NADR is the first dementia-focused registry in North Africa, aiming to collect biosamples, conduct cognitive assessments, and perform digital phenotyping [2] - The initiative will create a comprehensive multi-omics dataset to explore genetic and environmental factors related to Alzheimer's disease [2][3] - Data generated will be accessible via the Alzheimer's Disease Data Initiative (ADDI) platform, promoting global research collaboration [3] Group 2: Technological Partnership - PacBio will provide its advanced long-read sequencing technology to generate high-quality genomic data essential for understanding the genetic landscape of Alzheimer's disease [2][3] - The collaboration aims to identify new diagnostic tools and therapeutic solutions for Alzheimer's disease [3] Group 3: Importance of Diversity in Research - The project addresses the underrepresentation of North African populations in dementia research, which is crucial given the region's genetic diversity [2][3] - Insights gained from this research are expected to inform locally relevant prevention and intervention strategies [3] Group 4: Broader Implications - DAC aims to extend global research efforts beyond traditional Western populations to include diverse populations in the Global South, where most Alzheimer's patients reside [4] - The initiative aligns with DAC's goal to implement health system solutions that are globally applicable and to promote brain health throughout the lifespan [4][5]

Core Insights - The Davos Alzheimer's Collaborative (DAC) has partnered with PacBio to support the North African Dementia Registry (NADR) project, aiming to enhance understanding of Alzheimer's disease in North African populations [1][2][3] - This initiative is the first dementia-focused registry in North Africa, addressing the underrepresentation of these populations in dementia research [2][3] - The collaboration will utilize PacBio's long-read sequencing technology to create a comprehensive multi-omics dataset, facilitating research into genetic and environmental factors related to Alzheimer's disease [2][3] Company Insights - PacBio is recognized for its advanced sequencing solutions, which are crucial for generating high-quality genomic data necessary for understanding the complex genetic landscape of Alzheimer's disease [3][12] - The partnership aligns with PacBio's commitment to enabling genomic discoveries that improve human health globally [3][12] - The data generated from this collaboration will be accessible through the Alzheimer's Disease Data Initiative (ADDI) platform, promoting further research and innovation in Alzheimer's disease [3][4] Industry Insights - The DAC initiative aims to extend global research efforts beyond traditional Western populations to include diverse populations in the Global South, where a significant number of Alzheimer's cases exist [4] - By 2050, it is projected that over 150 million families and half a billion people will be affected by dementia, highlighting the urgent need for effective research and intervention strategies [4] - The NADR project will enable the collection of biosamples, cognitive assessments, and digital phenotyping, which are essential for developing locally relevant prevention and intervention strategies [2][3]